With the reimbursement imminent for the ultra-high-priced one-shot treatment Kymriah, the National Health Insurance Service is preparing to conduct research on the performance evaluation of the risk-sharing agreement (RSA) and its mid-to-long-term development direction.

The research will be exploring ways on the development direction of the RSA system through measures such as setting priorities in the reimbursement of ultra-high-priced one-shot treatments, etc.

On the 28th, the NHS made an urgent announcement for a bid on research services for the ' Performance Evaluation of the Risk Sharing Agreement Scheme.’

The research is expected to be completed by November this ye